Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD10 expression in diffuse large B-cell lymphomas does not influence survival.

Bettina Fabiani1, Alain Delmer, Eric Lepage

  • 1Département de Pathologie, Hôpital Saint-Antoine, AP-HP, Paris, France.

Virchows Archiv : an International Journal of Pathology
|November 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of systemic corticosteroids in ventilated patients with chronic obstructive pulmonary disease exacerbation: a systematic review and meta-analysis.

BMC pulmonary medicine·2026
Same author

Alpha-1 Antitrypsin Deficiency Alleles in Non-Cirrhotic Hepatocellular Carcinoma: Insights from a Multicenter French Cohort.

Journal of clinical and experimental hepatology·2026
Same author

[Hepatoblastoma for pathologists in 2025].

Annales de pathologie·2026
Same author

EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma.

Molecular cancer·2026
Same author

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Journal of hepatology·2026
Same author

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

EClinicalMedicine·2026
Same journal

Keratins and desmosomal proteins: Utility for molecular subtype identification in muscle-invasive bladder cancer.

Virchows Archiv : an international journal of pathology·2026
Same journal

Immunohistochemical profiling of ampullary carcinoma: Molecular subtypes, prognostic markers, and the role of Claudin-18.

Virchows Archiv : an international journal of pathology·2026
Same journal

Adult sialoblastoma harbouring FGFR2 p.C382R gene mutation.

Virchows Archiv : an international journal of pathology·2026
Same journal

Response to: comment on "FOXL2 expression in dysgenetic gonads supports the diagnostic possibility of ovotesticular differences of sex development".

Virchows Archiv : an international journal of pathology·2026
Same journal

Role of INSM1 expression in the diagnostic work-up of pancreatic acinar cell carcinoma with special reference to the differential diagnosis with neuroendocrine tumor.

Virchows Archiv : an international journal of pathology·2026
Same journal

Mismatch repair protein deficiency (MMRd) and high microsatellite instability (MSI-H) in gastrointestinal stromal tumour (GIST) - a case report and review of the literature of this exceedingly rare phenotype.

Virchows Archiv : an international journal of pathology·2026
See all related articles

CD10 expression in diffuse large B-cell lymphoma (DLBCL) does not correlate with clinical parameters or survival outcomes. This study found no significant impact of CD10 status on patient prognosis in DLBCL.

Area of Science:

  • Hematology
  • Oncology
  • Immunohistochemistry

Background:

  • CD10 expression is a recognized marker for centrofollicular-derived diffuse large B-cell lymphomas (DLBCL).
  • Understanding CD10's role is crucial for accurate DLBCL subtyping and prognostic assessment.

Purpose of the Study:

  • To investigate the correlation between CD10 expression and morphological features in DLBCL.
  • To assess the impact of CD10 expression on clinical parameters and survival outcomes in DLBCL patients.

Main Methods:

  • Retrospective analysis of 98 DLBCL patients from the GELA LNH93 trial.
  • Immunohistochemistry was used to determine CD10 expression.
  • Correlation with clinical parameters, International Prognostic Index (IPI), morphology, and survival data was analyzed.

Related Experiment Videos

Main Results:

  • 34% of DLBCL patients expressed CD10.
  • No significant correlation was found between CD10 expression and clinical parameters, IPI risk groups, or morphological subtypes.
  • Lower lactic dehydrogenase (LDH) levels were observed in CD10-negative cases (P=0.005).
  • CD10 expression did not significantly affect overall survival or event-free survival (P=0.44 and P=0.34, respectively).

Conclusions:

  • CD10 expression does not appear to be a significant prognostic factor in DLBCL patients treated with CHOP-like regimens.
  • The study suggests that CD10 status does not influence survival outcomes in DLBCL.
  • Morphological variations in centrofollicular-derived DLBCL can occur irrespective of CD10 expression.